Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2017 - 2025)

X4 Pharmaceuticals filings provide 9 years of Other Non-Current Liabilities readings, the most recent being $525000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 96.18% to $525000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $525000.0, a 96.18% decrease, with the full-year FY2025 number at $525000.0, down 96.18% from a year prior.
  • Other Non-Current Liabilities hit $525000.0 in Q4 2025 for X4 Pharmaceuticals, down from $959000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $29.4 million in Q1 2024 to a low of $283000.0 in Q2 2025.
  • Median Other Non-Current Liabilities over the past 5 years was $1.1 million (2023), compared with a mean of $6.3 million.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 2621.85% in 2023 and later tumbled 96.93% in 2025.
  • X4 Pharmaceuticals' Other Non-Current Liabilities stood at $496000.0 in 2021, then skyrocketed by 4565.52% to $23.1 million in 2022, then plummeted by 32.23% to $15.7 million in 2023, then decreased by 12.29% to $13.8 million in 2024, then plummeted by 96.18% to $525000.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $525000.0 (Q4 2025), $959000.0 (Q3 2025), and $283000.0 (Q2 2025) per Business Quant data.